-
Mashup Score: 0Use of Artificial Intelligence and Machine Learning in Clinical Practice | Lupus Science and Medicine Podcast - 11 hour(s) ago
Join Dr. Anna Wolska and Dr. May Choi as they explore the role of Artificial Intelligence (AI) and Machine Learning (ML) in guiding diagnostic and care decisions for systemic lupus erythematosus (SLE). Dr. Choi delves into key elements of machine learning and its potential impact on improving outcomes, particularly in underserved populations. She also discusses various types of machine learning, such as deep learning, supervised learning, and unsupervised learning, highlighting their respective contributions to enhancing efficiencies within clinical care settings. Read the related Review published in LSM: https://doi.org/10.1136/lupus-2023-001140
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5Homepage | Lupus Science & Medicine - 1 day(s) ago
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 1 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 1 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
New podcast exploring the role of Artificial Intelligence ( #AI ) and #MachineLearning ( #ML ) in guiding #diagnostic and #care decisions for systemic lupus erythematosus ( #SLE ). https://t.co/JIjb1AUQD6